Peer-reviewed veterinary case report
Blood clotting tests in dogs with sudden blindness from retinal
By Lynch, Alex M et al.·Published in Journal of veterinary internal medicine·2023·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Hemostatic profiles in dogs with sudden acquired retinal degeneration syndrome.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with sudden acquired retinal degeneration syndrome (SARDS) were found to have higher levels of blood clotting factors compared to healthy dogs. This condition can lead to irreversible blindness, and the study showed that dogs with SARDS were more hypercoagulable, meaning their blood was more prone to clotting. While both groups had some level of hypercoagulability, the dogs with SARDS had significantly higher levels. Understanding this connection could help veterinarians manage the health of dogs with SARDS better in the future.
People also search for: dog sudden blindness · SARDS in dogs · dog blood clotting issues · treatment for dog eye problems · why is my dog losing vision
Abstract
BACKGROUND: Sudden acquired retinal degeneration syndrome (SARDS) is a common cause of irreversible blindness in dogs. It bears clinical resemblance to hypercortisolism, which can be associated with hypercoagulability. The role of hypercoagulability in dogs with SARDS is unknown. OBJECTIVE: Determine hemostatic profiles in dogs with SARDS. ANIMALS: Prospective pilot study: Dogs with a history of SARDS (n = 12). Prospective case-control study: Dogs with recent onset of SARDS (n = 7) and age-, breed-, and sex-matched controls (n = 7). METHODS: Prospective pilot study: We performed thromboelastography (TEG). Prospective case-control study: Dogs had CBC, serum biochemistry, urinalysis, TEG, fibrinogen concentration, antithrombin activity, D-dimers, thrombin-antithrombin complexes, and optical platelet aggregometry performed. RESULTS: Prospective pilot study: 9/12 dogs with a history of SARDS were hypercoagulable with increased TEG G value and 2/3 had hyperfibrinogenemia. Case-control study: All dogs with SARDS and 5/7 controls were hypercoagulable based on TEG G value. Dogs with SARDS had significantly higher G values (median, 12.7 kdynes/s; range, 11.2-25.4; P = .04) and plasma fibrinogen concentration (median, 463 mg/dL; range, 391-680; P < .001) compared to controls. CONCLUSIONS AND CLINICAL IMPORTANCE: Hypercoagulability was common in both dogs with SARDS and controls, but dogs with SARDS were significantly more hypercoagulable on TEG. The role of hypercoagulability in the pathogenesis of SARDS remains to be determined.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37073895/